Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of January 2026, with a report date of January 16, 2026. The document serves as a report of a foreign private issuer regarding a material corporate governance event.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a board resignation and contains no financial statements or performance data.
Material Changes
The primary material change disclosed is the resignation of Yaacov Goldman from the Board of Directors and all associated committees, effective immediately on January 14, 2026. The Company states that Mr. Goldman resigned for personal reasons and explicitly notes there was no disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No new risks, contingencies, or unusual items were disclosed in this specific report.
Key Facts for Investor Verification
- Yaacov Goldman resigned from the Board of Directors effective January 14, 2026.
- The resignation was attributed to personal reasons with no stated disagreement with management.
- The filing does not include financial results or operational updates for the period.